FDA guidance on Postmarket Surveillance

shimonv

Trusted Information Resource
#1
Hi All,
For those of you who have not read the recent guidance document (attached), I wrote a summary of the main points using the text from the guidance.

If you are wise, keep away from it.:)

Cheers,
Shimon

=======================\\
Overview

1. Section 522 of the Act, 21 U.S.C. § 360l, authorizes FDA to require postmarket surveillance in the following instances:
• a class II or class III device for which failure of the device would be reasonably likely to have a serious adverse health consequence (section 522(a)(1)(A)(i) of the Act);
• a class II or class III device expected to have significant use in pediatric populations (section 522(a)(1)(A)(ii) of the Act);
• a class II or class III device intended to be implanted in the human body for more than one year (section 522(a)(1)(A)(iii)(I) of the Act); or
• a class II or class III device intended to be a life-sustaining or life-supporting device used outside of a user facility (section 522(a)(1)(A)(iii)(II) of the Act)

2. Section 522(a)(1)(A) of the Act specifies that the agency may issue a postmarket surveillance order at the time of device approval or clearance or any time thereafter.

3. The order of prospective postmarket surveillance period can be up to 36 months and sometimes even more.

The process

4. FDA may identify device issues that are appropriate for postmarket surveillance at any point during the life cycle of a device. Such issues may be identified through a variety of sources including analysis of adverse event reports, a recall or corrective action, post-approval data, review of premarket data, reports from other governmental authorities, or review of scientific literature.

5. When FDA identifies a potential issue with a device that may warrant postmarket surveillance, the Division of Epidemiology (DEPI), Office of Surveillance and Biometrics (OSB), Center for Devices and Radiological Health (CDRH) makes a determination regarding whether the statutory requirements for a section 522 order have been met. Next, the Division establishes a cross-Center team (i.e., pre-522 team) to review the issue in greater depth. This team may include FDA epidemiologists, clinicians, or other experts as needed to assess the issue. The pre-522 team evaluates numerous elements with the ultimate goal of making a recommendation to the DEPI Division Director and OSB Director as to whether or not a 522 order should be issued to address a public health question.

6. An order for postmarket surveillance under section 522 of the Act will generally be issued by the OSB Director. The 522 order should identify the premarket submission involved (i.e., 510(k), PMA, PDP, or HDE, or de novo petition), the public health questions, the rationale for the 522 order, and postmarket surveillance design recommendations to assist the manufacturer subject to the 522 order in preparing the postmarket surveillance plan. See 21 CFR 822.5. If a manufacturer disagrees with any order or condition requiring postmarket surveillance under section 522 of the Act, possible recourse options are described in 21 CFR 822.7.

7. FDA will assign a postmarket surveillance (PS) number (i.e., PS######) to each 522 order.

8. A manufacturer must submit a postmarket surveillance plan within 30 days of receipt of the 522 order and commence surveillance not later than 15 months after the day on which FDA issues the 522 order.

9. The general and specific content for a postmarket surveillance submission, including the surveillance plan, is outlined in 21 CFR 822.9 and 822.10. FDA will review all postmarket surveillance submissions and respond within 60 calendar days.

10. If a manufacturer disagrees with FDA about the content of the plan or if the plan is disapproved, possible recourse options are described in 21 CFR 822.22.

11. If a manufacturer wishes to propose a change to an approved postmarket surveillance plan that will affect the nature or validity of the data collected, the manufacturer must obtain FDA approval in writing before making such changes.

12. Failure to comply with a requirement under section 522 of the Act may result in enforcement action by FDA.

13. There are different types of postmarket surveillance: randomized clinical trials, prospective cohort study, retrospective cohort Study, cross-sectional study, enhanced surveillance, active surveillance, comprehensive, linked, registry-based surveillance, meta-analysis, prospective & retrospective study, case control study, bench/lab study, animal study, or other design.

14. As provided at 21 CFR 822.38, manufacturers must submit interim and final reports as specified in an approved postmarket surveillance plan.

15. FDA’s 522 webpage - http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm.

Summary
• In a nutshell, it is somewhat similar to the EU post-market clinical follow-up (PMCF) process only a lot more stringent.
• This guidance document authorizes FDA to order manufacturers to do postmart surveillance when one of the criteria set in point #1 are met, and when the agency believes that there is a public health question that must be addressed.
• It's good to keep an eye on FDA's 522 page to see who is getting such an order and way.
• The amount of effort required to fulfill a postmarket surveillance is enormous. It would be wise to keep it in mind and as part of our strategic plans.
 

Attachments

Elsmar Forum Sponsor
J

Julie O

#2
Thanks for digging into and summarizing this guidance.

I just wanted to give a little more perspective on the suggestion to "keep away from it."

Industry has actually been lobbying for more postmarket surveillance. This is not because they are necessarily eager to collect more clinical data, but because companies think they can negotiate down on the premarket clinical data requirements by offering to collect more data postmarket. It's still too soon to tell, but FDA seems to be open to this trade-off. For this reason, although FDA may issue an "order" for postmarket surveillance, often it will actually be the company that proposes it, in conjunction with a somewhat modest premarket clinical trial.

Because a clinical trial is often needed for design validation with these devices, the companies that market them usually don't find these post-market surveillance requirements to be quite as off-putting as companies that develop Class I and II devices that don't require clinical trial data. They are used to collecting clinical data and have developed the appropriate expertise. For some of these devices, the company would plan to do postmarket surveillance whether FDA ordered it or not, because of postmarket liability concerns. (For higher risk devices, I often refer to the first 3-5 years postmarket as "the litigation phase" of product development.)

As for staying away from them, if you are a device regulatory professional with little to no experience with devices requiring clinical trials, obviously this might not be something you want to get into. If your company wants to get into it, then we can hope (sigh) that they wouldn't burden you with it, but would secure the services of someone with this experience to handle it instead of you.

From the company's perspective, it isn't a choice of whether to stay away from post-market surveillance, but whether to stay away from the devices for which it is required. If the device has the market potential to warrant the investment, and the company has the expertise to conduct postmarket surveillance, they will probably not want to stay away from it. The headaches come if they try to pursue it without the appropriate expertise.
 
Thread starter Similar threads Forum Replies Date
shimonv FDA News FDA guidance on Multiple Function Device Products (8/2020) Other US Medical Device Regulations 1
K FDA Premarket Cybersecurity Guidance - 4 questions Other US Medical Device Regulations 5
S What is considered a "core algorithm"? (From an FDA guidance document) Medical Information Technology, Medical Software and Health Informatics 4
Stoic Are any medical device companies using the 2011 FDA process validation guidance instead of GHTF/SG3/N99-10:2004? 21 CFR Part 820 - US FDA Quality System Regulations (QSR) 1
M Informational US FDA Draft Guidance – Breast Implants – Certain Labeling Recommendations to Improve Patient Communication Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Final Guidance – Coronary, Peripheral, and Neurovascular Guidewires – Performance Tests and Recommended Labeling Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Final Guidance – Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings – Labeling Considerations Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Draft Guidance – Clinical Decision Support Software Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Draft Guidance – Providing Regulatory Submissions for Medical Devices in Electronic Format – Submissions Under Section 745A(b) of the Federal F Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Draft Guidance – Patient Engagement in Design and Conduct of Medical Device Clinical Investigations Medical Device and FDA Regulations and Standards News 0
M Informational FDA draft guidance – Safer Technologies Program for Medical Devices Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Final Guidance – Special Premarket Notification [510(k)] Pathway Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Final Guidance – Acceptance Review for De Novo Classification Requests Medical Device and FDA Regulations and Standards News 1
M Informational US FDA Final Guidance – Humanitarian Device Exemption (HDE) Program Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Final Guidance – Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classificati Medical Device and FDA Regulations and Standards News 0
M Informational US FDA draft guidance – Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Final guidance – Postmarketing Safety Reporting for Combination Products Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Final guidance – Metal Expandable Biliary Stents – Premarket Notification (510(k)) Submissions Medical Device and FDA Regulations and Standards News 0
M Informational US FDA final guidance – Marketing Clearance of Diagnostic Ultrasound Systems and Transducers Medical Device and FDA Regulations and Standards News 0
M Informational US FDA draft guidance. – Clinical Investigations for Prostate Tissue Ablation Devices Medical Device and FDA Regulations and Standards News 2
M Informational US FDA draft guidance – Mouse Embryo Assay for Assisted Reproduction Technology Devices Medical Device and FDA Regulations and Standards News 0
S Sterilization Site Move - Dec 2018 FDA Guidance Document 21 CFR Part 820 - US FDA Quality System Regulations (QSR) 1
M Informational US FDA final guidance – Utilizing Animal Studies to Evaluate Organ Preservation Devices Medical Device and FDA Regulations and Standards News 0
M Informational US FDA Guidance update – Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Medical Device and FDA Regulations and Standards News 0
M Informational US FDA final guidance Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices Medical Device and FDA Regulations and Standards News 0
Ronen E FDA News FDA issues guidance on bench testing in premarket submissions Other US Medical Device Regulations 0
M FDA Guidance - general wellness products - wearables Other Medical Device Related Standards 3
Ed Panek Website to ask FDA for guidance in Medical Device Industry? 21 CFR Part 820 - US FDA Quality System Regulations (QSR) 3
M Informational USFDA draft guidance – Nonbinding Feedback After Certain FDA Inspections of Device Establishments Medical Device and FDA Regulations and Standards News 0
D FDA filing guidance to add sterilization step for approved drug Pharmaceuticals (21 CFR Part 210, 21 CFR Part 211 and related Regulations) 8
Ajit Basrur FDA News FDA Guidance Document: Manufacturing Site Change Supplement US Food and Drug Administration (FDA) 0
M Medical Device News FDA Guidance - UDI: Policy Regarding Compliance Dates for Class I and Unclassified Devices and Certain Devices Requiring Direct Marking Other US Medical Device Regulations 0
AnaMariaVR2 Pharmaceuticals News Transdermal and Topical Delivery Systems: FDA & EMA Guidance US Food and Drug Administration (FDA) 0
M Medical Device News FDA News - 03-10-18 - CDRH FY 2019 Proposed Guidance Development and Focused Retrospective Review of Final Guidance Other US Medical Device Regulations 0
shimonv FDA released final guidance documents on what constitutes a significant change Other US Medical Device Regulations 2
shimonv Summary of FDA Guidance on “Medical Device Accessories” (Dec 2016) Other US Medical Device Regulations 1
M 2016 FDA Final Guidance for Blood Glucose Monitoring Systems - Implementation Other US Medical Device Regulations 2
M IEC 62304, ISO 14971 and FDA Medical Device SW Guidance 21 CFR Part 820 - US FDA Quality System Regulations (QSR) 5
Ronen E FDA releases new draft guidance on when to submit a 510(k) for device modification Other US Medical Device Regulations 10
Marc New FDA guidance on low-risk wellness devices US Food and Drug Administration (FDA) 1
Ronen E FDA issues draft guidance on form & content of UDI Other US Medical Device Regulations 0
planB Biocompatibility: Blue Book Memorandum #G95-1 superseded by new FDA guidance Other Medical Device Related Standards 1
Ronen E FDA issues draft guidance on additive manufacturing Other US Medical Device Regulations 1
D FDA Guidance Document for Preparing Annual Product Reviews US Food and Drug Administration (FDA) 2
B What is the FDA guidance regarding selling replacement parts and traceability? 21 CFR Part 820 - US FDA Quality System Regulations (QSR) 2
M New FDA Draft Guidance on 510(k) Ownership and Use Other US Medical Device Regulations 3
Marc FDA Issues Guidance On Cybersecurity of Medical Devices Other Medical Device and Orthopedic Related Topics 1
A FDA Medical Device Reprocessing Guidance - Validation US Food and Drug Administration (FDA) 6
R FDA's guidance - Evaluation of Sex-Specific Data in Medical Device Clinical Studies Other US Medical Device Regulations 3
bio_subbu FDA issues Guidance on UDI - Frequently Asked Questions, Vol. 1 Other US Medical Device Regulations 1

Similar threads

Top Bottom